Lycopene treatment against loss of bone mass, microarchitecture and strength in relation to regulatory mechanisms in a postmenopausal osteoporosis model

Autor: Abdulrahim A. Rouzi, Mohammed-Salleh M. Ardawi, Shaker A. Mousa, Nouf M. AlNosani, Mohammed H. Qari, Mohammed H. Badawoud, Jumanah M.S. Ardawi, Sherif M. Hassan
Rok vydání: 2016
Předmět:
0301 basic medicine
Deoxypyridinoline
Bone density
Physiology
Endocrinology
Diabetes and Metabolism
Bone remodeling
chemistry.chemical_compound
Absorptiometry
Photon
Lycopene
0302 clinical medicine
Bone Density
Femur
Osteoporosis
Postmenopausal
Minerals
Lumbar Vertebrae
Osteoblast
Organ Size
Biomechanical Phenomena
Enzymes
medicine.anatomical_structure
8-Hydroxy-2'-Deoxyguanosine
Ovariectomized rat
Female
Bone Remodeling
medicine.medical_specialty
Histology
030209 endocrinology & metabolism
Bone and Bones
Bone resorption
03 medical and health sciences
Osteoclast
Internal medicine
medicine
Animals
Humans
Bone Resorption
Rats
Wistar
Tibia
business.industry
Body Weight
Uterus
Deoxyguanosine
X-Ray Microtomography
Humerus
Carotenoids
Hormones
Disease Models
Animal
030104 developmental biology
Endocrinology
chemistry
Cortical bone
Diaphyses
business
Biomarkers
Zdroj: Bone. 83:127-140
ISSN: 8756-3282
DOI: 10.1016/j.bone.2015.10.017
Popis: Lycopene supplementation decreases oxidative stress and exhibits beneficial effects on bone health, but the mechanisms through which it alters bone metabolism in vivo remain unclear. The present study aims to evaluate the effects of lycopene treatment on postmenopausal osteoporosis. Six-month-old female Wistar rats (n=264) were sham-operated (SHAM) or ovariectomized (OVX). The SHAM group received oral vehicle only and the OVX rats were randomized into five groups receiving oral daily lycopene treatment (mg/kg body weight per day): 0 OVX (control), 15 OVX, 30 OVX, and 45 OVX, and one group receiving alendronate (ALN) (2μg/kg body weight per day), for 12weeks. Bone densitometry measurements, bone turnover markers, biomechanical testing, and histomorphometric analysis were conducted. Micro computed tomography was also used to evaluate changes in microarchitecture. Lycopene treatment suppressed the OVX-induced increase in bone turnover, as indicated by changes in biomarkers of bone metabolism: serum osteocalcin (s-OC), serum N-terminal propeptide of type 1 collagen (s-PINP), serum crosslinked carboxyterminal telopeptides (s-CTX-1), and urinary deoxypyridinoline (u-DPD). Significant improvement in OVX-induced loss of bone mass, bone strength, and microarchitectural deterioration was observed in lycopene-treated OVX animals. These effects were observed mainly at sites rich in trabecular bone, with less effect in cortical bone. Lycopene treatment down-regulated osteoclast differentiation concurrent with up-regulating osteoblast together with glutathione peroxidase (GPx) catalase (CAT) and superoxide dismutase (SOD) activities. These findings demonstrate that lycopene treatment in OVX rats primarily suppressed bone turnover to restore bone strength and microarchitecture.
Databáze: OpenAIRE
Externí odkaz: